Opinion
Video
Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
Author(s):
The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.
Related Videos
Related Content
